Image : https://www.who.int/images/default-source/searo---images/health-topics/corona-virus19/coronavirus-blue.jpg?sfvrsn=1bdbbe71_12

Don D. Sin

European Respiratory Journal 2023 61: 2202272; DOI: 10.1183/13993003.02272-2022

Extract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for the novel coronavirus disease of 2019 (COVID-19), has, to date (27 December, 2022), infected over 662 million people and been directly responsible for 6.6 million deaths worldwide [1]. Millions of patients who have recovered from COVID-19 continue to experience one or more COVID-19-related symptoms, including fatigue, intractable headaches, exertional dyspnoea, olfactory and taste disturbances, myalgia and cognitive dysfunction (also called “brain fog”) for many weeks to months following their acute illness [2].

The findings from the study reported by Mukherjee and co-workers suggest that autoreactive antibodies may be responsible for driving the inflammatory process that persist in patients with long COVID https://bit.ly/3hAnDkt

Footnotes

• Conflict of interest: D.D. Sin has received small honoraria from AstraZeneca, Boehringer Ingelheim and GSK for giving lectures on COPD, and is chair of a data monitoring committee for a NHLBI-sponsored clinical trial in COPD.

• Support statement: D.D. Sin is a Tier 1 Canada Research Chair in COPD and holds the de Lazzari Family Chair at the Centre for Heart Lung Innovation.

• Received November 28, 2022.
• Accepted December 10, 2022.

• Copyright ©The authors 2023. For reproduction rights and permissions contact permissions@ersnet.org